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Effect of dietary ascorbate on covalent binding of benzene to bone marrow and 
bepatic tissue in viva* 
(Received 29 October 1985; accepted 14 February 1986) 
Benzene produces aplastic anemia in humans and is a 
human leukemogen [ 1,2]. The biochemical mechanics 
whereby benzene produces these effects are presently 
unknown. However, several reports have demonstrated a 
relationship between covalent binding in the bone marrow, 
the target site, and benzene-induced blood dyscrasia in 
laboratory animals [3,4]. Toxicity appears to be the result 
of the metabolic activation of benzene [5,6]. Ascorbate 
has been shown to be effective in preventing the in vitro 
covalent binding of the metabolites of benzene and phenol, 
the major metabolite of benzene [7-91. We have demon- 
strated previously that, when phenol and hydrogen per- 
oxide are incubated with bone marrow preparations 
isolated from guinea pigs with low ascorbate tissue con- 
centration, there is a 4-fold increase in in vitro covalent 
binding of phenol equivalents to bone marrow tissue when 
compared to guinea pigs on a high ascorbate intake [9]. 
Ascorbate cannot be synthesized in the guinea pig or human 
and must be procured through dietary intake, and the 
concentrations of ascorbate in tissue can vary widely from 
individual to individual due to their respective dietary 
intake [lo]. In the present communication, we have inves- 
tigated the effect of ascorbate on covalent binding of 
[r4C]benzene metabolites in vivo. To evaluate the effect of 
ascorbate on covalent binding in viuo, guinea pigs were 
placed on different dietary intakes of ascorbate followed 
by i.p. administration of [‘4C]benzene. 
* This work was supported in part by Grant 23007 from 
Hoffmann-La Roche, Nutley, NJ. 
Covalent binding was inversely related to dietary ascor- 
bate intake and to the concentration of ascorbate in both 
liver and bone marrow. Covalent binding was altered by 2- 
and 1.4-fold in the liver and bone marrow respectively. The 
concentration of ascorbate in bone marrow and hepatic 
tissue ranged from 0.12 to 2.63 moles/g tissue depending 
upon the dietary intake. 
Three groups of four male Hartley guinea pigs (200- 
250g) were placed on the following dietary intakes of 
ascorbate: 2.0, 0.35 and 0.05 mg ascorbate/ml drinking 
water for 4 weeks prior to the i.p. administration of 
benzene. All guinea pigs received ascorbate-deficient 
guinea pig chow ad lib. (ICN Nutritional Biochemicals, 
Cleveland, OH). The growth rate for each group of guinea 
pigs was not significantly different. The guinea pigs on the 
lowest intake showed no signs of a scorbutic condition. 
After 4 weeks on the diets, each guinea pig was injected 
with 660 mg/kg [“‘Clbenzene intraperitoneallv twice, 12 
and 6 hr before‘ termination. The specific -activity of 
1i4Clbenzene was either 52.7 or 15.2 uCi/uol. I’4C1Benzene 
was’injected in 0.5 ml corn oil. Six hours after the second 
injection the guinea pigs were terminated by decapitation. 
Each liver was removed, and a 20% homogenate was made 
with 100mM sodium phosphate buffer, pH 7.4. Femurs 
were removed from each guinea pig, and the bone marrow 
was scraped out of the femoral cavity. Each marrow sample 
was weighed and a 10% homogenate was prepared. Hepatic 
homogenate (2504) and bone marrow homogenate 
(1.2 ml) were extracted, and the covalently bound benzene 
equivalents in these tissues were determined by the method 
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of Tunek et al. [ll]. Bone marrow and hepatic ascorbate 
concentrations were measured in these guinea pigs by the 
method of Zannoni et al. 1121. 
The concentrations of &c&bate in bone marrow and 
liver of the benzene-treated guinea pigs are shown in Table 
1. There was approximately a lo-fold difference in the 
ascorbate tissue concentration in both liver and bone mar- 
row when the low dietary intake of ascorbate was compared 
to the high. As shown in Fig. 1, covalent binding of benzene 
metabolites to hepatic tissue was decreased as the hepatic 
ascorbate tissue concentration was increased. Covalent 
binding to hepatic tissue was decreased in the order of 2- 
fold when the hepatic ascorbate tissue concentration was 
increased approximately lo-fold. Covalent binding of 
benzene equivalents to bone marrow tissue also varied 
inversely with ascorbate tissue concentration (Fig. 2). Bone 
marrow ascorbate tissue concentration could also be modu- 
lated over lo-fold, while covalent binding could be 
decreased 1 .Cfold. 
In the present communication we have demonstrated 
that ascorbate is capable of altering the covalent binding 
of benzene metabolites to hepatic or bone marrow tissue 
in vivo. Covalent binding was inversely related to ascorbate 
intake and to the concentration of ascorbate in these tissues. 
The difference in covalent binding between groups may be 
important with regard to the myelotoxicity of benzene since 
several investigators have shown that a decrease in covalent 
binding to bone marrow tissue results in the decreased 
toxicity of benzene [3,4]. 
The differences in covalent binding are small when com- 
pared to the differences in the concentration of ascorbate 
in these tissues. We have demonstrated previously that 
ascorbate via its antioxidant activity is capable of inhibiting 
the in vitro covalent binding of the metabolites of phenol by 
over 90% and, when benzene is employed as the Hubstrati, 
covalent binding is inhibited bv 35% and this changes onlv 
slightly when tie concentration of ascorbate is i&crease; 
from 1 to 5 mM [9]. Similarly, in the present study the in 
uivo covalent binding of benzene equivalents after i.p. 
administration of benzene was decreased 30%, while the 
bone marrow ascorbate concentration was altered lo-fold. 
These data may suggest that the reactive species responsible 
for the observed covalent binding is only slightly refractory 
or non-refractory to the antioxidant effect of ascorbic acid. 
This is in keeping with the concept that the major species 
responsible for the observed in vivo covalent binding may 
not be the oxidized forms (hydroquinone, catechol or 
phenol) since we have demonstrated previously that ascor- 
bic acid is very effective in reducing these metabolites and 
thus preventing their interaction with tissue macro- 
molecules [B, 91. Another possible explanation to consider 
is that the cellular distribution of ascorbate is such that it 
is not at a substantial concentration at the site of reactive 
metabolite formation. Nevertheless, the dietary intake of 
ascorbate does alter the covalent binding of benzene metab- 
elites to both bone marrow and hepatic tissue in vivo, 
and this event in the bone marrow is associated with the 
myelotoxicity of benzene [3,4]. 
0.i6 O.ks 2.k 
average hepatic ascorbate level, umol/g 
Fig. 1. Covalent binding of the metabolites of benzene in Fig. 2. Covalent binding of the metabolites of benzene in 
the liver after i.p. administration of [14C]benzene. 
[14C]Benzene (660 mg/kg) was administered 12 and 6 hr 
the bone marrow after i.p. administration of [14C]benzene. 
before termination to three groups of guinea pigs on dif- 
[14C]Benzene (660 mg/kg) was administered 12 and 6 hr 
ferent dietary intakes of ascorbate. Ascorbate and binding 
before termination to three groups of guinea pigs on dif- 
values were determined for each guinea pig, and the values 
ferent dietary intakes of ascorbate. Ascorbate and binding 
are expressed as the mean f standard deviation. P < 0.01 
values were determined for each guinea pig and the values 
are expressed as the mean + standard deviation. P < 0.01 
with respect to 0.12 pmole/g ascorbate to 1.84. with respect to 0.28 pmole/g ascorbate to 2.63. 
0.i2 O.iS l.ci4 
average bone marrow ascorbate level, umol/g 
Table 1. Ascorbate concentration in liver and bone marrow of guinea pigs on the 
three dietary regimens of ascorbate 




2.0 Ascorbate/ml drinking water mg 
0.35 mn Ascorbate/ml drinking water 
2.63 f 0.49 1.84 + 0.24 
0.43 f 0.11 0.46 2 0.17 
0.05 mg Ascorbatejml drinking water 0.28 f 0.06 0.12 f 0.02 
Values are expressed as the mean * standard deviation of four guinea pigs/dietary 
intake. 
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Endocytosis of proteins by kidney tubule cells: inhibition by the aminoglycoside 
gentamicin 
Nephrotoxicity is a major limitation to the long term use 
of aminoglycoside antibiotics such as gentamicin. This 
nephrotoxicity is associated with damage to both kidney 
glomerulus and tubule and is dependent on such factors as 
dose, duration of exposure, age and sex [l]. Early renal 
dysfunction has been related to the accumulation of amino- 
glycosides in the lysosomes of proximal tubule cells [2,3]. 
Gentamicin also accumulates in lysosomes of other cell 
types such as fibroblasts [4] as has been shown for other 
weak bases [5]. 
Proximal tubule cells in the kidney are responsible for 
the reabsorption and degradation of protein remaining after 
ultrafiltration in the glomerulus [6]. It has been suggested 
[7] that an initial event in normal tubular protein reab- 
sorption is an interaction between the protein and an 
anionic binding site at the proximal tubule brush border. 
Additionally, competition for such sites by polycationic 
aminoglycosides appears to take place [8]. Thus the effect 
of gentamicin on the renal handling of proteins is of interest. 
We have recently used a kidney cell line-Madin Darby 
Canine Kidney (MDCK) cells-to study the selectivity in 
adsorptive endocytosis of different size proteins by tubular 
cells [9]. The present study utilises this cell line to inves- 
tigate the effects of gentamicin on the uptake and degra- 
dation of rat plasma proteins. 
Materials and methods 
MDCK cells were maintained in monolayer culture in 
Eagles minimum essential medium (MEM) (Flow Lab- 
oratories) supplemented with 10% heat inactivated foetal 
calf serum and antibiotics. Rat serum (Miles Laboratories, 
Bucks, U.K.) was inactivated by heating at 56” for 30 min 
and then separated into three molecular size fractions by 
gel filtration on a Sepharose 6B column (Pharmacia, 
Sweden). Gel electrophoresis on 7.5% non-denaturing gel 
in Tris-glycine pH 8.9 showed the largest molecular size 
fraction to contain predominantly macroglobulins. The 
intermediate size fraction comprised gammaglobulins with 
some albumin and the smallest molecular size fraction 
contained albumin and the smaller proteins. Aliquots of 
concentrated fractions were iodinated using the iodogen 
method [lo] and the reaction products dialysed against 
DhosDhate buffered saline [PBS) after which less than 2% 
bf thk radioactivity was soluble ‘in 5% trichloroacetic acid 
(TCA). Competition studies (data not show) indicated that 
the iodinated protein was recognised in a similar manner 
to the unlabelled protein as would be expected with the 
mild iodination procedure employed. All reagents were of 
the best available commercial grade. 
MDCK cells were seeded at low density and allowed to 
grow to confluence over a period of 5 days in the presence 
of gentamicin (Flow Laboratories) in the concentration 
range 250-1000 yg/ml of culture medium. For the measure- 
ment of endocytosis, [3H]-sucrose (Amersham Interna- 
tional) or ‘251-labelled proteins were then presented to the 
resultant confluent cell monolayers in fresh serum sup- 
plemented culture medium containing gentamicin such that 
gentamicin was present throughout the experimental period 
at the same concentrations as used in the preincubations. 
At the commencement of uptake the confluent monolayer 
consisted of viable cells and viability was maintained 
throughout the experiments as judged by morphology and 
retention of cell protein in the monolayer. 
In order to measure uptake and degradation at chosen 
times after addition of the substrate, the media were har- 
vested and the cells washed four times with ice-cold PBS 
to remove extracellular radioactivity. The cells were then 
lysed by the addition of 0.1% Triton X-100 in PBS. To 
measure uptake and degradation, media and cell fractions 
were precipitated with 5% TCA and TCA soluble and 
insoluble fractions counted separately by a gamma counter 
(Ultragamma 1280, LKB) or, for [3H]-sucrose uptake, ali- 
quots counted directly in a liquid scintillation counter 
(Packard Tricarb 460C). An aliquot of each cell sample 
was assayed for protein by the method of Lowry et al. 
[ 1 l] using bovine serum albumin as standard. Uptake was 
